Find us on Social Media:

What is it? Overview Usage Side Effects and Warnings

Mesoglycan Usage

Written by FoundHealth.

Therapeutic Uses

Most proposed uses of mesoglycan involve diseases of blood vessels. For example, evidence suggests that mesoglycan may slow the development of hardening of the arteries , perhaps by lowering cholesterol levels , "thinning" the blood, or through other effects. 1 People with severe hardening of the arteries sometimes develop blockage in the arteries of the legs, a condition called intermittent claudication . This condition limits the ability to walk by causing intense, crampy pain after walking a relatively short distance. There is some evidence that mesoglycan may help. 2 The conditions just discussed involve arteries. Mesoglycan may also be useful for various diseases of the veins, including varicose veins/venous insufficiency , hemorrhoids , and phlebitis . 3 One study suggests that a substance related to mesoglycan, hyaluronic acid, might be helpful for asthma when taken by inhalation. 4

Warning: Do not self-treat phlebitis. It is a potentially deadly disease.

Preliminary evidence suggests mesoglycan may additionally be useful in treating kidney stones . 5 The substance chondroitin is used for the treatment of osteoarthritis . Based on the chemical similarities between chondroitin and mesoglycan, researchers conducted a large (almost 400 participant) 5-year, double-blind, placebo-controlled study of injected mesoglycan for slowing the progression of osteoarthritis. 6 Unfortunately, no benefits were seen.


  1. Laurora G, Cesarone MR, Belcaro G, et al. Control of the progress of arteriosclerosis in high risk subjects treated with mesoglycan. Measuring the intima media [translated from Italian]. Minerva Cardioangiol. 1998;46:41–47.
  2. Nenci GG, Gresele P, Ferrari G, Santoro L, Gianese F, Mesoglycan Intermittent Claudication Group. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb Haemost. 86(5):1181-7.
  3. Petruzzellis V, Velon A. Therapeutic action of oral mesoglycan in the pharmacologic treatment of the varicose syndrome and its complications [in Italian; English abstract]. Minerva Med. 1985;76:543–548.
  4. Petrigni G, Allegra L. Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma. Pulm Pharmacol Ther. 2006 Jan 3 [Epub ahead of print]
  5. Baggio B, Gambaro G, Marchini F, Marzaro G, Williams HE, Borsatti A. Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans. Lancet. 338(8764):403-5.
  6. Pavelka K, Gatterova J, Gollerova V, et al. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon®) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000;8:335–342.


No one has made any comments yet. Be the first!

Your Comment